Disease latency and new‐user versus prevalent‐user cohort designs: Implications for pharmacoepidemiology in dementia
Journal of the American Geriatrics Society · 2024
DOI: 10.1111/jgs.18714 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the American Geriatrics Society, 2024. Verfasst von Che-Yuan Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Pharmacoepidemiology, Dementia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: CIHR, Canadian Institutes of Health Research.
Themen: Demenz
Abstract (Originalsprache)
See the Reply by Lee et al . in this issue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
- Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada.
- KITE University Health Network Toronto Rehabilitation Institute, Toronto, Ontario, Canada.
ORCID-Profile: Walter Swardfager
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Wu, C. Y., & Swardfager, W. (2024). Disease latency and new‐user versus prevalent‐user cohort designs: Implications for pharmacoepidemiology in dementia. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.18714
Vancouver
Wu CY, Swardfager W. Disease latency and new‐user versus prevalent‐user cohort designs: Implications for pharmacoepidemiology in dementia. Journal of the American Geriatrics Society. 2024. doi:10.1111/jgs.18714
BibTeX
@article{Wu2024,
author = {Wu, Che-Yuan and Swardfager, Walter},
title = {Disease latency and new‐user versus prevalent‐user cohort designs: Implications for pharmacoepidemiology in dementia},
journal = {Journal of the American Geriatrics Society},
year = {2024},
doi = {10.1111/jgs.18714}
}
EUVIMED